← Back

Goodrx Holdings Inc

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Price · split & dividend adjusted
News & notes moving GDRX
GDRX

GoodRx Stock Looks Full on Earnings but Mixed on Value

GoodRx Holdings stock screens as overvalued on earnings multiples, with a current price-to-earnings ratio of about 48.6 times, above a tailored fair ratio estimate of roughly 35.5 times and the broader healthcare services industry average of about 26.4 times, though below its peer group average near 56.2 times. The company scores 3 out of 6 on Simply Wall St's broader valuation checks, indicating a mixed picture rather than a clear bargain or clear overvaluation. Over the past five years, the stock has declined about 90%, and it delivered negative 37.8% returns over the last year. Community narratives diverge, with a bull case suggesting the stock could be 26% undervalued based on subscription-driven upside, while a bear case sees it as 31% overvalued due to potential regulatory pressures on drug pricing.
GDRX
Simply Wall St·47dRead more ▾
GDRX▲

Online Counseling Market to Reach $4.85 Billion by 2030

The global online counseling market is projected to grow from $3.03 billion in 2025 to $4.85 billion by 2030, according to a new report from ResearchAndMarkets.com. The market is expected to reach $3.34 billion in 2026, reflecting a compound annual growth rate of 10.1%, driven by rising mental health awareness, telehealth adoption, and increased smartphone and internet penetration. Growth through 2030 is forecast at a CAGR of 9.8%, supported by AI-driven therapy tools, personalized mental health care demand, and employer-sponsored wellness programs. North America dominated the market in 2025, and key players include Teladoc Health, GoodRx, Thriveworks, Doctor On Demand, and Talkspace. The report covers 14 major countries including the USA and UK, and notes that tariffs on imported IT equipment may raise costs for North American and European providers while accelerating cloud-based models.
TALK ▲TDOC ▲GDRX ▲
GlobeNewswire·49dRead more ▾
GDRX▼

StockStory picks Amgen and Medpace as healthcare stocks to watch, brushes off GoodRx

StockStory highlights Amgen and Medpace as healthcare stocks with sustainable market-beating potential while recommending investors avoid GoodRx. Amgen, with a market cap of $191.1 billion, posted 12.3% annual revenue growth over two years on a $37.22 billion base and generates strong free cash flow. Medpace, valued at $13.57 billion, achieved 16.9% organic revenue growth and expanded its free cash flow margin by 8.3 percentage points over five years. GoodRx, in contrast, saw flat sales and negative returns on capital, with a revenue base of $787.9 million that lacks scale. Amgen trades at $346.68 per share, Medpace at $513.06, and GoodRx at $2.76.
AMGN ▲GDRX ▼MEDP ▲
Yahoo Finance·63dRead more ▾
GDRX▼

GoodRx Q1 revenue beats estimates but declines 4.4% year on year

GoodRx reported first-quarter revenues of $194 million, down 4.4% year on year, exceeding analysts' expectations by 4.9%. The company also provided full-year revenue guidance that slightly topped estimates. Among the seven healthcare technology stocks tracked, GoodRx posted the slowest revenue growth, while the group overall beat consensus revenue estimates by 1.6% and issued in-line next-quarter guidance. Omnicell delivered the best performance with revenues of $309.9 million, up 14.9% year on year, and Hims & Hers Health was the weakest, with revenues of $608.1 million missing estimates by 1.4%. Astrana Health achieved the fastest revenue growth at 55.6% year on year, and Tandem Diabetes raised its full-year guidance the most among peers.
GDRX ▼HIMS ▼OMCL ▲TNDM ▲ASTH ▲
StockStory·70dRead more ▾
© 2026 MarketDXAsset